HC Wainwright Predicts Weaker Earnings for Beam Therapeutics

Key Points

• HC Wainwright trimmed near‑term and multi‑year EPS forecasts, cutting Q1 2026 to ($0.91) from ($0.88) and lowering FY2026–FY2029 estimates (FY2026 now ($3.74), FY2027 ($3.60), FY2028 ($2.69), FY2029 ($1.99)), a negative catalyst for sentiment and valuation.
• Despite the cuts, Beam posted a big recent beat — $2.33 EPS vs consensus ($1.13) and revenue of $114.11 million (vs $13.22M expected), up 280% year‑over‑year largely due to licensing/one‑time payments.
• Analyst coverage is mixed but tilted positive: the consensus rating is a Moderate Buy (most analysts Rate Buy) with an average target of $46.19, while the stock trades near $27.44 (market cap ≈ $2.8B).

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for shares of Beam Therapeutics in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.91) per share for the quarter, down from their prior estimate of ($0.88). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics' Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($3.74) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($1.99) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $2.33 earnings per share for the quarter, topping the consensus estimate of ($1.13) by $3.46. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The company had revenue of $114.11 million during the quarter, compared to analysts' expectations of $13.22 million. During the same period in the prior year, the firm earned ($1.09) earnings per share. Beam Therapeutics's revenue for the quarter was up 280.3% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. Tudor Pickering set a $41.00 price target on Beam Therapeutics in a research report on Wednesday, January 21st. Sanford C. Bernstein upped their price target on shares of Beam Therapeutics from $37.00 to $41.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 20th. Wedbush boosted their target price on Beam Therapeutics from $57.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. Finally, Wall Street Zen raised shares of Beam Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $46.19.

Beam Therapeutics Stock Up 0.8%

NASDAQ:BEAM opened at $27.44 on Thursday. The company has a market cap of $2.80 billion, a P/E ratio of -27.17 and a beta of 2.12. Beam Therapeutics has a twelve month low of $13.52 and a twelve month high of $36.44. The business has a 50 day moving average price of $28.91 and a two-hundred day moving average price of $25.40.

Institutional Trading of Beam Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BEAM. Allworth Financial LP boosted its holdings in shares of Beam Therapeutics by 7,080.0% during the 2nd quarter. Allworth Financial LP now owns 2,513 shares of the company's stock valued at $43,000 after acquiring an additional 2,478 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Beam Therapeutics in the fourth quarter valued at about $47,000. Larson Financial Group LLC boosted its stake in shares of Beam Therapeutics by 4,370.5% during the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company's stock valued at $48,000 after purchasing an additional 1,923 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Beam Therapeutics by 48.7% during the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company's stock worth $52,000 after purchasing an additional 707 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Beam Therapeutics in the fourth quarter valued at approximately $59,000. Institutional investors own 99.68% of the company's stock.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 18,629 shares of the business's stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $34.61, for a total transaction of $644,749.69. Following the completion of the transaction, the insider owned 97,038 shares of the company's stock, valued at approximately $3,358,485.18. The trade was a 16.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is currently owned by corporate insiders.

Key Beam Therapeutics News

Here are the key news stories impacting Beam Therapeutics this week:

• Neutral Sentiment: HC Wainwright published new forward estimates for 2027–2030 (quarterly and full‑year EPS projections). These are model updates rather than a change in coverage — useful for framing long‑term expectations but not an immediate operational update. HC Wainwright issues 2027–2030 estimates
• Neutral Sentiment: Short‑interest postings for early March show inconsistent/zero values (the report lists “0 shares” and NaN changes). The data appears unreliable and shouldn’t be treated as a clear signal of rising bearish positioning. Monitor for corrected filings if you trade on short interest. Short interest report (March)
• Negative Sentiment: HC Wainwright lowered near‑term and multi‑year EPS forecasts across Q1–Q4 2026 and FY2026–FY2029 (e.g., Q1–Q4 2026 EPS nudged lower; FY2026 cut to –$3.74 from –$3.53; FY2028/2029 estimates also reduced). These downward revisions are a direct negative catalyst — they signal the analyst expects slower margin/earnings progression than previously modeled and can weigh on sentiment and valuation multiples for this development‑stage biotech. HC Wainwright cuts 2026–2029 estimates

About Beam Therapeutics

Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.